GYRE vs. ANIP, MORF, AKRO, RCUS, DAWN, KURA, IRWD, KNSA, LGND, and DVAX
Should you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include ANI Pharmaceuticals (ANIP), Morphic (MORF), Akero Therapeutics (AKRO), Arcus Biosciences (RCUS), Day One Biopharmaceuticals (DAWN), Kura Oncology (KURA), Ironwood Pharmaceuticals (IRWD), Kiniksa Pharmaceuticals (KNSA), Ligand Pharmaceuticals (LGND), and Dynavax Technologies (DVAX). These companies are all part of the "pharmaceutical preparations" industry.
Gyre Therapeutics (NASDAQ:GYRE) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, community ranking, earnings, dividends and profitability.
ANI Pharmaceuticals has higher revenue and earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Gyre Therapeutics has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 2.9% of Gyre Therapeutics shares are held by insiders. Comparatively, 12.7% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
ANI Pharmaceuticals has a net margin of 3.86% compared to Gyre Therapeutics' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 18.06% beat Gyre Therapeutics' return on equity.
ANI Pharmaceuticals received 425 more outperform votes than Gyre Therapeutics when rated by MarketBeat users.
In the previous week, ANI Pharmaceuticals had 7 more articles in the media than Gyre Therapeutics. MarketBeat recorded 10 mentions for ANI Pharmaceuticals and 3 mentions for Gyre Therapeutics. ANI Pharmaceuticals' average media sentiment score of 0.14 beat Gyre Therapeutics' score of 0.03 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.
ANI Pharmaceuticals has a consensus price target of $80.00, suggesting a potential upside of 22.40%. Given ANI Pharmaceuticals' higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Gyre Therapeutics.
Summary
ANI Pharmaceuticals beats Gyre Therapeutics on 14 of the 16 factors compared between the two stocks.
Get Gyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gyre Therapeutics Competitors List
Related Companies and Tools
